Novel regulator inhibits toxic protein aggregates in Huntington's disease
Advertisement
Huntington's disease is a neurodegenerative disorder characterized by huntingtin protein aggregates in a patient's brain, but how these aggregates form is not well understood. In a study published in Genome Research, researchers developed a novel computational strategy to identify interaction partners of the huntingtin protein and discovered a novel factor that suppresses misfolding and aggregation.
Huntington's disease is caused by an expansion of glutamine residues in the huntingtin protein, altering its function and ultimately resulting in toxic aggregation of huntingtin fragments in neurons. Proteins that interact with the glutamine-expanded huntingtin protein are thought to strongly influence the formation of the aggregates.
"The challenge that remains is if there are many proteins interacting with the huntingtin protein, we cannot easily determine which are relevant for disease and which are not," said Erich Wanker from Max Delbrück Center for Molecular Medicine and corresponding author of the study.
By combining large datasets of protein-protein interactions and filtering by brain-specific gene expression in patients with and without Huntington's disease, the scientists narrowed potential interactors to 13 candidates, including 7 that are known targets in Huntington's disease.
The researchers followed up on one candidate, CRMP1, because of its expression in brain and not elsewhere in the body. Using cell-based model systems and Drosophila, they found CRMP1 overexpression reduces hungtingtin aggregation and cellular toxicity, while reduced CRMP1 results in increased aggregation and toxicity. In cell-free assays, CRMP1 slows the spontaneous self-assembly of huntingtin fragments with glutamine expansions.
"CRMP1 was not regarded as a therapeutic target so far, now it is worth exploring as a potential target," said Wanker.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Research demonstrates millions of plastic particles exist in cosmetic products
MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award
Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear
Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc. - Total alliance milestones more than double to over €400 million, plus royalties on worldwide sales
Dharmacon Named Best Reagent Company at RNAi-2004-Boston Meeting on RNA
to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment
Marine biomedicine researchers decode structure of promising sea compound - Novel natural product yielding potential new ways to fight diseases
The Medical Research Council and GATC Biotech sign Sequencing Contract
